Sol-Gel Analyst & Investor Day 2019 in NYC

Maxwell Hotel, July 25, 2019

General Agenda

The event will include updates regarding our clinical development programs, commercial plans, and plans for advancing new pipeline candidates into clinical studies.

The event will feature presentations by management and leading dermatologists including:

  • Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System
  • Jeffrey Sugarman, MD, PhD, Medical Director Northern California Medical Associates, Assoc. Clinical Professor, University of California, San Francisco
  • Mori Arkin, Chairman of The Board of Directors
  • Alon Seri-Levy, PhD, Co-Founder and Chief Executive Officer
  • John Vieira, U.S. Head of Commercialization

Click for Webcast

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Sol-Gel Technologies Ltd. [SLGL] US$159 MM MCap
Com­mer­cial­iz­ing brand­ed gener­ic top­i­cal drug prod­ucts (skin dis­eas­es). Two pos­i­tive Phase 3 pro­grams in rosacea and acne, with NDAs ex­pect­ed in 1H20 and 2H20, re­spec­tive­ly. Ad­di­tio­n­al brand­ed pipe­line as­sets in­clude SGT-210, er­lo­tinib, for the treat­ment of punc­tu­ate pal­mo­plan­tar ker­a­to­der­ma, and pre­clin­i­cal as­set tap­i­narof and rof­lu­mi­last. Sol-Gel al­so has rev­enue from sev­er­al gener­ic col­lab­o­ra­tions. [more in­for­ma­tion]

Event Contact

Joy Willis
Solebury Trout

Location of the Event and Other Places